PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold. PYLCLARI® (INN: Piflufolastat (18F) also known as (18 F)-DCFPyL, is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:
See the rest here:
Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate...
Recommendation and review posted by G. Smith
